ONCT News and Press, Oncternal Therapeutics Inc. From 01/08/24

SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the fourth patient has now been enrolled into its Phase 1/2 study of ONCT-534, its dual...

2024-01-08 08:02:08 ET Oncternal Therapeutics Inc (ONCT) announced stock split at a ratio of 1-for-20 on 2024-01-08 ... Full story available on KlickAnalytics.com

2024-01-04 09:11:30 ET More on Oncternal Therapeutics Oncternal slips after early data for lymphoma therapy Oncternal stock jumps 9% on FDA fast track designation For further details see: Oncternal Therapeutics announces a reverse stock split

SAN DIEGO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that its board of directors (Board) has approved a 1-for-20 reverse stock split of the compa...

2023-12-26 11:02:48 ET Oncternal Therapeutics ( NASDAQ: ONCT ) traded lower on Tuesday after announcing initial results from its Phase 1/2 study for autologous CAR T cell therapy, ONCT-808-101, in patients with B-cell lymphoma, a cancer affecting the immune system. Citing data f...

SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today updated the status of its dose escalation/dose expansion Phase 1/2 Study ONCT-808-101, evaluating the ...

2023-11-09 21:07:09 ET Oncternal Therapeutics, Inc. (ONCT) Q3 2023 Earnings Conference Call November 09, 2023, 17:00 ET Company Participants Richard Vincent - CFO James Breitmeyer - President and CEO Salim Yazji - Chief Medical Officer Conference Call Parti...

2023-11-09 16:16:15 ET More on Oncternal Therapeutics Oncternal stock jumps 9% on FDA fast track designation Seeking Alpha’s Quant Rating on Oncternal Therapeutics Historical earnings data for Oncternal Therapeutics Financial information for Oncternal ...

The first patient was dosed in our Phase 1/2 study for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitors Additional patients were treated in our ongoing Phas...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...